Radiation oncology as a profession is in a period of retrenchment due to the economic crisis. There is also a growing demand from payors to show value for these treatments, said ASTRO President Anthony Zeitman, M.D. He says the technologies used need to undergo rigorous clinical testing to show what works best and what is most cost-effective. Part of ASTRO's push is for a national registry to help advance this data collection.
If you enjoy this content, please share it with a colleague
Related Content
May 6, 2026 — GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT2, a solution designed to ...
April 30, 2026 — The Siemens Healthineers business area, Varian, has been awarded up to $60 million over five years by ...
April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...
April 10, 2026 — The radiation therapy team at The Ohio State University Wexner Medical Center, The James Cancer ...
April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...
The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...
March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...
March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...
Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...
Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...
May 06, 2026 